Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions
June 04 2019 - 7:00AM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new
analyses of clinical data for sotagliflozin will be presented at
the upcoming 79th American Diabetes Association (ADA) Scientific
Sessions in San Francisco, California. The five accepted posters
reflect Lexicon and its collaborator, Sanofi’s efforts to address
the unmet need and potential treatment options for the management
of type 1 diabetes.
ePosters
- Saturday, June 8, 11:30am, Exhibit Hall (ePoster Theater B);
ePoster Session “The Latest on SGLT Inhibition”
- Sotagliflozin Reduces Glucose Variability and Risk for
Hyperglycemia in Adults with Type 1 Diabetes (1191-P)
- The Impact of Sotagliflozin on Renal Function, Albuminuria and
Blood Pressure in Adults with Type 1 Diabetes (1196-P)
Posters
- Sunday, June 9, 12:00pm, General Poster Session, Poster Hall
(Hall F, North, Exhibition Level)
- Sotagliflozin Reduces Markers of Arterial Stiffness in
T1D: Pooled Analysis from InTandem1 and InTandem2 Clinical
Trials (1212-P)
- Sotagliflozin Leads to Lower Rates of Clinically Relevant
Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with
T1D (1220-P)
- Burden of Cardiovascular Comorbidity in US Adults with T1D
(168-LB)
- ePosters listed above also presented during this session
About
Sotagliflozin
Discovered using Lexicon’s unique approach to
gene science, sotagliflozin is an investigational oral dual
inhibitor of two proteins responsible for glucose regulation known
as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
SGLT1 is responsible for glucose absorption in the gastrointestinal
tract, and SGLT2 is responsible for glucose reabsorption by the
kidney.
Zynquista™ (sotagliflozin) has been
approved in the European Union for use as an adjunct to insulin
therapy to improve glycemic control in adults with type 1 diabetes
and a body mass index ≥ 27 kg/m2, who could not achieve adequate
glycemic control despite optimal insulin therapy. Sotagliflozin has
not yet been approved for use in any other jurisdiction.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company that is applying a unique approach to gene science based on
Nobel Prize-winning technology to discover and develop precise
medicines for patients with serious, chronic conditions. Through
its Genome5000™ program, Lexicon scientists have studied the role
and function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s and
Sanofi’s clinical development of and regulatory filings for
sotagliflozin and the potential therapeutic and commercial
potential of sotagliflozin. In addition, this press release also
contains forward-looking statements relating to Lexicon’s growth
and future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including the risk that the FDA and other regulatory authorities
may not grant regulatory approval of sotagliflozin in accordance
with Lexicon’s currently anticipated timelines or at all, and the
risk that such regulatory approvals, if granted, may have
significant limitations on the approved use of sotagliflozin. As a
result, sotagliflozin may never be successfully commercialized.
Other risks include Lexicon’s ability to meet its capital
requirements, successfully commercialize XERMELO (telotristat
ethyl), successfully conduct preclinical and clinical development
and obtain necessary regulatory approvals of LX2761, LX9211 and its
other potential drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon’s actual results to be materially different from any
future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under “Risk Factors” in Lexicon’s annual report on Form
10-K for the year ended December 31, 2018, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024